Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia.

Abstract:

:TAL1/SCL is a prime example of an oncogenic transcription factor that is abnormally expressed in acute leukemia due to the replacement of regulator elements. This gene has also been recognized as an essential regulator of hematopoiesis. TAL1 expression is strictly regulated in a lineage- and stage-specific manner. Such precise control is crucial for the switching of the transcriptional program. The misexpression of TAL1 in immature thymocytes leads to a widespread series of orchestrated downstream events that affect several different cellular machineries, resulting in a lethal consequence, namely T-cell acute lymphoblastic leukemia (T-ALL). In this article, we will discuss the transcriptional regulatory network and downstream target genes, including protein-coding genes and non-coding RNAs, controlled by TAL1 in normal hematopoiesis and T-cell leukemogenesis.

journal_name

Int J Hematol

authors

Tan TK,Zhang C,Sanda T

doi

10.1007/s12185-018-2518-z

subject

Has Abstract

pub_date

2019-01-01 00:00:00

pages

5-17

issue

1

eissn

0925-5710

issn

1865-3774

pii

10.1007/s12185-018-2518-z

journal_volume

109

pub_type

杂志文章,评审
  • Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era.

    abstract::Allogeneic hematopoietic stem cell transplantation (HSCT) and tyrosine kinase inhibitor have revolutionized the treatment of patients with chronic myeloid leukemia (CML). In this study, the clinical impact of HSCT and imatinib mesylate (IM) was retrospectively analyzed in 28 children with CML treated in our institutes...

    journal_title:International journal of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s12185-010-0764-9

    authors: Muramatsu H,Takahashi Y,Sakaguchi H,Shimada A,Nishio N,Hama A,Doisaki S,Yagasaki H,Matsumoto K,Kato K,Kojima S

    更新日期:2011-02-01 00:00:00

  • Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical h

    abstract::Bortezomib is a proteasome inhibitor that can be effective in the treatment of refractory and relapsed multiple myeloma. Recently, severe pulmonary complications associated with bortezomib therapy have been reported in Japan. Because bortezomib has not yet been approved for general use in Japan and is imported by atte...

    journal_title:International journal of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1532/IJH97.06142

    authors: Gotoh A,Ohyashiki K,Oshimi K,Usui N,Hotta T,Dan K,Ikeda Y

    更新日期:2006-12-01 00:00:00

  • Phagocytosis of co-developing neutrophil progenitors by dendritic cells in a culture of human CD34(+) cells with granulocyte colony-stimulating factor and tumor necrosis factor-alpha.

    abstract::Tumor necrosis factor-alpha (TNF-alpha) has been shown to induce the differentiation of CD34(+) cells toward dendritic cells (DCs). We have previously shown that DCs are co-generated from human CD34(+) cells during erythroid or megakaryocytic differentiation in the presence of TNF-alpha, and those DCs are able to stim...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-008-0098-z

    authors: Saito Y,Guo YM,Hirokawa M,Saito K,Komatsuda A,Takahashi N,Fujishima M,Fujishima N,Yamashita J,Sawada K

    更新日期:2008-07-01 00:00:00

  • Benefit of simultaneous rhG-CSF and methylprednisolone 'pulse' therapy for methotrexate-induced bone marrow failure in rheumatoid arthritis.

    abstract::A 74-year-old female with seropositive rheumatoid arthritis developed severe bone marrow failure after the treatment with very low-dose methotrexate (5 mg/week for 3 weeks). Hematological data showed severe pancytopenia with 0% neutrophils and bone marrow disclosed thoroughly hypocellular marrow. Shortly after the tre...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1016/s0925-5710(96)00549-x

    authors: Kondo H,Date Y

    更新日期:1997-02-01 00:00:00

  • Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.

    abstract::Several clinical trials have demonstrated the effectiveness of bortezomib in combination with various anti-myeloma agents; however, no definitive information is available regarding drugs best suited for use in combination with bortezomib. Using isobologram analysis, we investigated the combined effects of bortezomib w...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-014-1573-3

    authors: Kikuchi J,Koyama D,Mukai HY,Furukawa Y

    更新日期:2014-06-01 00:00:00

  • Comparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: a systematic review and meta-analysis.

    abstract::To prevent thromboembolic events associated with heparin-induced thrombocytopenia (HIT), patients usually are treated with argatroban, lepirudin, and bivalirudin. Here, we conducted a meta-analysis of studies to comparing the treatment of HIT with the following direct thrombin inhibitor: argatroban versus lepirudin an...

    journal_title:International journal of hematology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s12185-017-2271-8

    authors: Sun Z,Lan X,Li S,Zhao H,Tang Z,Xi Y

    更新日期:2017-10-01 00:00:00

  • A novel gene, ANKRD28 on 3p25, is fused with NUP98 on 11p15 in a cryptic 3-way translocation of t(3;5;11)(p25;q35;p15) in an adult patient with myelodysplastic syndrome/acute myelogenous leukemia.

    abstract::We identified a novel gene fusion of ANKRD28 (ankyrin repeat domain 28) on 3p25 to NUP98 on 11p15 in a patient with adult myelodysplastic syndrome/acute myelogenous leukemia. A partially cryptic 3-way translocation, t(3;5;11)(p25;q35;p15), that had initially been supposed to be t(3;5)(p25;q35) was revealed by precise ...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1532/IJH97.07054

    authors: Ishikawa M,Yagasaki F,Okamura D,Maeda T,Sugahara Y,Jinnai I,Bessho M

    更新日期:2007-10-01 00:00:00

  • Dominant beta-thalassemia with hemoglobin Hradec Kralove: enhanced hemolysis in the spleen.

    abstract::We describe a 6-year-old girl and her mother with dominant beta-thalassemia due to hemoglobin Hradec Kralove (Hb HK). Both patients presented microcytic anemia, jaundice, splenomegaly, cholelithiasis, and recurrent hemolytic bouts. Osmotic resistance tests using saline and coiled planet centrifugation revealed the inc...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/BF02983557

    authors: Ohga S,Nomura A,Takada H,Kato J,Ideguchi H,Hattori Y,Suda M,Suita S,Hara T

    更新日期:2003-11-01 00:00:00

  • No major role for the transcription factor NF-κB in bone marrow function during peritonitis in the mouse.

    abstract::Nuclear factor-kappa B (NF-κB) is a multipotent transcription factor that plays a pivotal role in immune reactions, inflammation, and possibly hematopoiesis as well. Mobilization of neutrophilic granulocytes during inflammation is a highly regulated process, but one that is incompletely understood. We studied the in v...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-014-1598-7

    authors: Knudsen E,Carlsen H,Bøyum A,Benestad HB,Iversen PO

    更新日期:2014-08-01 00:00:00

  • Prognostic value of Waldeyer's ring involvement of diffuse large B-cell lymphoma treated with R-CHOP.

    abstract::The objective of present study was to compare the prognosis of diffuse large B-cell lymphoma (DLBCL) with Waldeyer's ring involvement (WR-DLBCL) to that of nodal DLBCL (N-DLBCL) without WR involvement. Between July 2004 and October 2009, medical records and metabolic tumor volume (MTV) measured by 2-[fluorine-18]-fluo...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-013-1282-3

    authors: Oh MY,Chung JS,Song MK,Shin HJ,Lee HS,Lee SM,Lee GW,Lee SE

    更新日期:2013-03-01 00:00:00

  • Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles.

    abstract::Recent evidence suggests that mesenchymal stem cells (MSC) selectively home to tumors, where they contribute to the formation of tumor-associated stroma. This effect can be opposed by genetically modifying MSC to produce high levels of anti-cancer agents that blunt tumor growth kinetics and inhibit the growth of tumor...

    journal_title:International journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1532/IJH97.06230

    authors: Hall B,Dembinski J,Sasser AK,Studeny M,Andreeff M,Marini F

    更新日期:2007-07-01 00:00:00

  • Correction to: Effect of sertraline on complications and survival after hematopoietic stem-cell transplantation, a double-blind, placebo-controlled clinical study.

    abstract::The correct name of the corresponding author should be ''Maryam Mehrpooya'', and not ''Mehrpooya Maryam'' as given in the original publication of the article. ...

    journal_title:International journal of hematology

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s12185-017-2372-4

    authors: Tavakoli-Ardakani M,Kheshti R,Mehrpooya M

    更新日期:2018-01-01 00:00:00

  • Induction of erythroid-specific genes by overexpression of GATA-2 in K562 cells.

    abstract::GATA transcription factors have been shown to play important roles in hematopoiesis. GATA-2 is expressed in stem and progenitor cells, and has been speculated to control the proliferation and maintain the immaturity of these cells. To examine whether the function of GATA-2 is changeable according to the differentiatio...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1532/IJH97.06020

    authors: Harigae H,Okitsu Y,Yokoyama H,Fujiwara T,Inomata M,Takahashi S,Minegishi N,Kaku M,Sasaki T

    更新日期:2006-07-01 00:00:00

  • Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.

    abstract::Abnormal platelet-derived growth factor receptor (PDGFR)-mediated signaling may cause hematologic neoplasm. The PDGFR beta (PDGFRB) gene, located at chromosome band 5q31-33, forms a fusion gene as a result of chromosome translocation. Although patients with PDGFRB rearrangement mostly present with myeloproliferative n...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-016-2167-z

    authors: Shimomura Y,Maruoka H,Ishikawa T

    更新日期:2017-05-01 00:00:00

  • Myelodysplastic syndrome in a patient with a unique constitutional chromosome abnormality t(2;11) (q31;p13).

    abstract::We present a case of myelodysplastic syndrome (MDS), which developed into an overt leukemic phase in a 15-year-old female with a rare constitutional abnormality [46,XX,t(2;11) (q31;p13)]. The patient entered complete remission after 3 months of chemotherapy. On chromosome analysis during remission, the t(2;11) (q31;p1...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:

    authors: Hinoda Y,Itoh H,Takahashi T,Adachi M,Tsujisaki M,Imai K,Yachi A

    更新日期:1992-08-01 00:00:00

  • Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.

    abstract::Bortezomib and melphalan have synergistic effects against multiple myeloma (MM) cells. We conducted a pilot study on the combination of bortezomib and high-dose melphalan (Bor-HDM) as a conditioning regimen followed by autologous stem cell transplant (ASCT) in 17 Japanese patients with newly diagnosed MM, in compariso...

    journal_title:International journal of hematology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s12185-013-1402-0

    authors: Miyamoto T,Yoshimoto G,Kamimura T,Muta T,Takashima S,Ito Y,Shiratsuchi M,Choi I,Kato K,Takenaka K,Iwasaki H,Takamatsu Y,Teshima T,Akashi K

    更新日期:2013-09-01 00:00:00

  • Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity.

    abstract::The plasma levels of soluble urokinase-type plasminogen activator receptor (uPAR; CD87) measured by enzyme-linked immunosorbent assay were higher in patients with paroxysmal nocturnal hemoglobinuria (PNH) (5.8 +/- 4.7 ng/ml, mean +/- S.D., n = 9) than in normal donors (2.0 +/- 0.8 ng/ml, mean +/- S.D., n = 15). The hi...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1016/s0925-5710(96)00559-2

    authors: Ninomiya H,Hasegawa Y,Nagasawa T,Abe T

    更新日期:1997-04-01 00:00:00

  • Increased frequency of monoclonal gammopathy of undetermined significance in patients with nonimmune chronic idiopathic neutropenia syndrome.

    abstract::This study describes the frequency of monoclonal gammopathy of undetermined significance (MGUS) and the changes in some inflammation-related serum proteins in 157 patients with nonimmune chronic idiopathic neutropenia syndrome (NI-CINS). Of these patients, 42 had pronounced neutropenia with neutrophil counts < 1500/mi...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/BF02981959

    authors: Papadaki HA,Eliopoulos DG,Ponticoglou C,Eliopoulos GD

    更新日期:2001-04-01 00:00:00

  • Current status of ex vivo gene therapy for hematological disorders: a review of clinical trials in Japan around the world.

    abstract::Gene therapies are classified into two major categories, namely, in vivo and ex vivo. Clinical trials of human gene therapy began with the ex vivo techniques. Based on the initial successes of gene-therapy clinical trials, these approaches have spread worldwide. The number of gene therapy trials approved worldwide inc...

    journal_title:International journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1007/s12185-016-2030-2

    authors: Tani K

    更新日期:2016-07-01 00:00:00

  • Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.

    abstract::A phase 1/2 study was conducted to assess the safety and efficacy of dasatinib in Japanese patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL) resistant or intolerant to imatinib. In phase 1, 18 patients with chronic phase (CP) CML were treated ...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-009-0260-2

    authors: Sakamaki H,Ishizawa KI,Taniwaki M,Fujisawa S,Morishima Y,Tobinai K,Okada M,Ando K,Usui N,Miyawaki S,Utsunomiya A,Uoshima N,Nagai T,Naoe T,Motoji T,Jinnai I,Tanimoto M,Miyazaki Y,Ohnishi K,Iida S,Okamoto S,Seriu

    更新日期:2009-04-01 00:00:00

  • Trend and treatment patterns of aplastic anemia in Korea, pure red cell aplasia and myelodysplastic syndrome in Korea: a nation-wide analysis.

    abstract::Aplastic anemia (AA) and pure red cell aplasia (PRCA) appear to be more prevalent in Asian countries including Korea. However, there are no exact data regarding its prevalence and frequency of allogeneic hematopoietic cell transplantation (HCT) in Korea. Here, we present demographic data relating to AA/PRCA/MDS in Kor...

    journal_title:International journal of hematology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s12185-017-2280-7

    authors: Choi Y,Jo JC,Jeon HJ,Kim DW,Chang MH,Kim H

    更新日期:2017-10-01 00:00:00

  • Dendritic cells: sentinels of immunity and tolerance.

    abstract::The induction of effective antigen-specific T-cell immunity to pathogens without the initiation of autoimmunity has evolved as a sophisticated and highly balanced immunoregulatory mechanism. This mechanism assures the generation of antigen-specific effector cells as well as the induction and maintenance of antigen-spe...

    journal_title:International journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1532/IJH97.04165

    authors: Kubach J,Becker C,Schmitt E,Steinbrink K,Huter E,Tuettenberg A,Jonuleit H

    更新日期:2005-04-01 00:00:00

  • Stem and progenitor cells in human umbilical cord blood.

    abstract::Both stem cells and progenitor cells are present in umbilical cord blood (UCB) at a high frequency, making these cells a major target population for experimental and clinical studies. As the use of autologous or allogeneic hematopoietic stem cell transplantation in the treatment of various diseases has grown rapidly i...

    journal_title:International journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1007/s12185-010-0619-4

    authors: Lee MW,Jang IK,Yoo KH,Sung KW,Koo HH

    更新日期:2010-07-01 00:00:00

  • Dilated cardiomyopathy during the course of hemolytic uremic syndrome.

    abstract::A 47-year-old woman presented with severe hemolytic uremic syndrome (HUS) followed by heart failure. An echocardiogram showed an ejection fraction of 20%, and a cardiac catheterization followed by a myocardial histologic evaluation demonstrated dilated cardiomyopathy. Plasma exchange and hemodialysis were performed re...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1532/IJH97.E0713

    authors: Alexopoulou A,Dourakis SP,Zovoilis C,Agapitos E,Androulakis A,Filiotou A,Archimandritis AJ

    更新日期:2007-11-01 00:00:00

  • Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR.

    abstract::A.R.R.O.W. evaluated the superiority of once-weekly carfilzomib plus dexamethasone (Kd) 20/70 mg/m2 vs. twice-weekly Kd 20/27 mg/m2 based on progression-free survival (PFS) in relapsed and/or refractory multiple myeloma patients. Forty Japanese patients (once-weekly arm, n = 26; twice-weekly arm, n = 14) were randomiz...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-020-03013-6

    authors: Takezako N,Shibayama H,Handa H,Hagiwara S,Ozaki S,Suzuki K,Kosugi H,Ri M,Sugiura I,Choi I,Miyamoto T,Iida S

    更新日期:2020-10-10 00:00:00

  • The role of the AML1 transcription factor in leukemogenesis.

    abstract::Chromosomal translocations are one of the hallmarks of human leukemias. These structural abnormalities result in the generation of genetic mutations that play a direct role in the transformation of hematopoietic stem cells. Some of the most common targets of these chromosomal rearrangements are the genes that encode t...

    journal_title:International journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1007/BF02982058

    authors: Lorsbach RB,Downing JR

    更新日期:2001-10-01 00:00:00

  • Recent advance in molecular iron metabolism: translational disorders of ferritin.

    abstract::Ferritin, composed of H-subunits and L-subunits, plays important roles in iron storage and in the control of intracellular iron distribution. Synthesis of both subunits is controlled by common cytoplasmic proteins, iron regulatory proteins (IRP-1 and IRP-2) that bind to the iron-responsive element (IRE) in the 5'-untr...

    journal_title:International journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1007/BF02982789

    authors: Kato J,Niitsu Y

    更新日期:2002-10-01 00:00:00

  • The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis.

    abstract::We conducted a retrospective analysis to evaluate the impact on clinical outcomes of adding rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment for diffuse large B-cell lymphoma (DLBCL) patients in Japan. A propensity score method was used to compensate for the non-randomized study...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-009-0259-8

    authors: Nishimori H,Matsuo K,Maeda Y,Nawa Y,Sunami K,Togitani K,Takimoto H,Hiramatsu Y,Kiguchi T,Yano T,Yamane H,Tabayashi T,Takeuchi M,Makita M,Sezaki N,Yamasuji Y,Sugiyama H,Tabuchi T,Kataoka I,Fujii N,Ishimaru F,Shin

    更新日期:2009-04-01 00:00:00

  • Successful unrelated bone marrow transplantation for a human immunodeficiency virus type-1-seropositive acute myelogenous leukemia patient following HAART.

    abstract::The availability of highly active anti-retroviral therapy (HAART) has greatly improved the outcome of human immunodeficiency virus type-1 (HIV-1) infection and disease. We report here on a case of an HIV-1-seropositive patient with acute myelogenous leukemia who underwent a successful allogeneic unrelated bone marrow ...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-009-0467-2

    authors: Oka Y,Tashiro H,Mizutani-Noguchi M,Koga I,Sugao T,Shirasaki R,Miura T,Akiyama N,Kawasugi K,Fujimori S,Shirafuji N

    更新日期:2010-01-01 00:00:00

  • Treatment outcomes of adolescent acute lymphoblastic leukemia treated on Tokyo Children's Cancer Study Group (TCCSG) clinical trials.

    abstract::There is no standard treatment for adolescents aged 15 years or older with acute lymphoblastic leukemia (ALL), although this age group has been reported as having a poorer prognosis compared to younger patients. We retrospectively analyzed the outcomes of three consecutive Tokyo Children's Cancer Study Group ALL trial...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-014-1622-y

    authors: Kato M,Manabe A,Koh K,Inukai T,Kiyokawa N,Fukushima T,Goto H,Hasegawa D,Ogawa C,Koike K,Ota S,Noguchi Y,Kikuchi A,Tsuchida M,Ohara A

    更新日期:2014-08-01 00:00:00